Literature DB >> 21440078

Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease.

Bryan M Grogan1, Laura Tabellini, Barry Storer, Tara E Bumgarner, Claudia C Astigarraga, Mary E D Flowers, Stephanie J Lee, Paul J Martin, Edus H Warren, John A Hansen.   

Abstract

We tested the hypothesis that changes in the phenotype of CD8(+) T cells from patients with chronic graft-versus-host disease (cGVHD) correlate with disease activity, and resolve or normalize in clinically tolerant patients successfully withdrawn from immunosuppression therapy (IST). No significant difference was found in the absolute CD8(+) T cell counts among cGVHD patients, tolerant patients, and healthy controls. However, compared with healthy normal controls, CD8(+) T cells from cGVHD patients had decreased expression of the IL-7 receptor and an increase in effector T cells, Ki-67, and perforin expression and apoptosis, suggesting that activation, differentiation, and proliferation of host-reactive CD8(+) effector T cells is a mechanism by which cGVHD is sustained and persists. The increase in effector T cells was most prominent in older patients and patients who were cytomegalovirus seropositive before transplantation. Use of IST was associated with a decreased number of CD45RA(-) CD8(+) effector T cells, a decreased expression of Ki-67, and an increased expression of CD95 (Fas). Together, these results demonstrate that CD8(+) T cells in patients with cGVHD are characterized by an increased level of activation and proliferation, and an expansion of effector cells that appear to be selectively sensitive to IST compared with other CD8(+) T cells. In GVHD-free tolerant patients, CD8(+) T cells showed an increased expression of granzyme and HLA-DR molecules compared with CD8(+) T cells from healthy controls, indicating that clinical tolerance in these patients can occur without full normalization of the CD8(+) T cell phenotype.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21440078      PMCID: PMC3177538          DOI: 10.1016/j.bbmt.2011.03.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  26 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.

Authors:  Lydie Trautmann; Loury Janbazian; Nicolas Chomont; Elias A Said; Sylvain Gimmig; Benoit Bessette; Mohamed-Rachid Boulassel; Eric Delwart; Homero Sepulveda; Robert S Balderas; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sekaly
Journal:  Nat Med       Date:  2006-08-20       Impact factor: 53.440

3.  Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation.

Authors:  K Weinberg; B R Blazar; J E Wagner; E Agura; B J Hill; M Smogorzewska; R A Koup; M R Betts; R H Collins; D C Douek
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

4.  Assessment of the Th1/Th2 paradigm in whole blood in atopy and asthma. Increased IFN-gamma-producing CD8(+) T cells in asthma.

Authors:  A O Magnan; L G Mély; C A Camilla; M M Badier; F A Montero-Julian; C M Guillot; B B Casano; S J Prato; V Fert; P Bongrand; D Vervloet
Journal:  Am J Respir Crit Care Med       Date:  2000-06       Impact factor: 21.405

5.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Authors:  Cheryl L Day; Daniel E Kaufmann; Photini Kiepiela; Julia A Brown; Eshia S Moodley; Sharon Reddy; Elizabeth W Mackey; Joseph D Miller; Alasdair J Leslie; Chantal DePierres; Zenele Mncube; Jaikumar Duraiswamy; Baogong Zhu; Quentin Eichbaum; Marcus Altfeld; E John Wherry; Hoosen M Coovadia; Philip J R Goulder; Paul Klenerman; Rafi Ahmed; Gordon J Freeman; Bruce D Walker
Journal:  Nature       Date:  2006-08-20       Impact factor: 49.962

6.  PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion.

Authors:  Simona Urbani; Barbara Amadei; Daniela Tola; Marco Massari; Simona Schivazappa; Gabriele Missale; Carlo Ferrari
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

7.  Chronic graft-versus-host disease after allogeneic blood stem cell transplantation.

Authors:  D Przepiorka; P Anderlini; R Saliba; K Cleary; R Mehra; I Khouri; Y O Huh; S Giralt; I Braunschweig; K van Besien; R Champlin
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

8.  Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals.

Authors:  S Chidrawar; N Khan; W Wei; A McLarnon; N Smith; L Nayak; P Moss
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

9.  Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Mats Remberger; Gunilla Kumlien; Johan Aschan; Lisbeth Barkholt; Patrik Hentschke; Per Ljungman; Jonas Mattsson; Johan Svennilson; Olle Ringdén
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

10.  Analysis of memory and effector CD8+ T cell subsets in chronic graft-versus-host disease.

Authors:  M D' Asaro; A Salerno; F Dieli; N Caccamo
Journal:  Int J Immunopathol Pharmacol       Date:  2009 Jan-Mar       Impact factor: 3.219

View more
  7 in total

1.  Increased Th17/Treg ratio in chronic liver GVHD.

Authors:  F Malard; C Bossard; E Brissot; P Chevallier; T Guillaume; J Delaunay; J-F Mosnier; P Moreau; M Grégoire; B Gaugler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

2.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivors.

Authors:  Nancy Bunin; Trudy Small; Paul Szabolcs; K Scott Baker; Michael A Pulsipher; Troy Torgerson
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-17       Impact factor: 5.742

3.  Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.

Authors:  Javier Bolaños-Meade; Juan Wu; Brent R Logan; John E Levine; Vincent T Ho; Amin M Alousi; Daniel J Weisdorf; Leo Luznik
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-12       Impact factor: 5.742

Review 4.  Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research.

Authors:  J W Mays; H Fassil; D A Edwards; S Z Pavletic; C W Bassim
Journal:  Oral Dis       Date:  2012-10-28       Impact factor: 3.511

5.  Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression.

Authors:  Birgit Sawitzki; Claudio Brunstein; Christian Meisel; Julia Schumann; Katrin Vogt; Christine Appelt; Julie M Curtsinger; Michael R Verneris; Jeffrey S Miller; John E Wagner; Bruce R Blazar
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-01       Impact factor: 5.742

6.  Identification of oral risk factors for chronic graft versus host disease in haematological patients who underwent allogeneic haematopoietic stem cell transplantation.

Authors:  A Picardi; M Miranda; F Liciani; G Paterno; W Arcese; P Bollero
Journal:  Oral Implantol (Rome)       Date:  2017-01-21

7.  Inducible T-Cell Co-Stimulator Impacts Chronic Graft-Versus-Host Disease by Regulating Both Pathogenic and Regulatory T Cells.

Authors:  Mengmeng Zhang; Yongxia Wu; David Bastian; Supinya Iamsawat; Jinsam Chang; Anusara Daenthanasanmak; Hung D Nguyen; Steven Schutt; Min Dai; Fangping Chen; Woong-Kyung Suh; Xue-Zhong Yu
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.